Study Evaluates VR Device for Anxiety and Pain in Interventional Radiology
The HYPNO-VR study could redefine pain and anxiety management in interventional radiology by validating VR as a non-pharmacological alternative. Success in this trial may prompt pharma companies to reevaluate their strategies and consider integrating VR technologies into their offerings.
Phase III
Anxiety / Non-Pharmacological Intervention
Status
Active
Sponsor
HYPNO-VR
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
The HYPNO-VR study could redefine pain and anxiety management in interventional radiology by validating VR as a non-pharmacological alternative. Success in this trial may prompt pharma companies to reevaluate their strategies and consider integrating VR technologies into their offerings.
Why it matters
The HYPNO-VR study could redefine pain and anxiety management in interventional radiology by validating VR as a non-pharmacological alternative. Success in this trial may prompt pharma companies to reevaluate their strategies and consider integrating VR technologies into their offerings.
What changed
Trial Update
Analysis
The HYPNO-VR study aims to assess the effectiveness of VR headset in reducing anxiety and pain during interventional radiology procedures.
The HYPNO-VR study could redefine pain and anxiety management in interventional radiology by validating VR as a non-pharmacological alternative. Success in this trial may prompt pharma companies to reevaluate their strategies and consider integrating VR technologies into their offerings.
Monitor results from the trial, particularly the primary outcomes related to anxiety and pain reduction, as well as patient satisfaction metrics.
Related companies & assets
Companies
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.